DSP-0390
Recurrent High-Grade Glioma
Key Facts
About Sumitomo Pharma
Sumitomo Pharma's mission is to translate cutting-edge science into innovative therapies that address significant unmet medical needs, particularly in psychiatry and oncology. The company has achieved global recognition through its commercialized products like Latuda® (lurasidone) and is advancing a robust pipeline of next-generation modalities. Its strategy hinges on a balanced portfolio, combining revenue-generating assets with high-risk, high-reward R&D in gene therapy and radiopharmaceuticals, supported by strategic global partnerships and internal discovery capabilities.
View full company profileTherapeutic Areas
Other Recurrent High-Grade Glioma Drugs
| Drug | Company | Phase |
|---|---|---|
| DB107 (Toca 511 & Toca FC) | Denovo Biopharma | Phase 2/3 |
| NanO₂ | NuvOx Therapeutics | Phase II |
| SRN-101 | Siren Biotechnology | Phase 1 |
| CAN-3110 | Candel Therapeutics | Phase 1 |